

## Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting

August 23, 2017

As announced in the February 2017 Ontario Drug Benefit (ODB) Formulary update, the Thyroid (desiccated thyroid) 30mg (DIN 00023949), 60mg (DIN 00023957) and 125mg (DIN 00023965) Tablets were delisted from the ODB Formulary. The delisting was effective February 28, 2017.

A six-month transition period (until August 31, 2017) was provided to enable existing patients on the drug (a prescription filled for one of the three strengths between September 1, 2016 and February 27, 2017) to consult their physicians and determine a suitable alternative therapy. A reminder notice was also sent out with the July 2017 Formulary update.

The transition approvals expire on August 31, 2017. Health care providers are reminded again to plan accordingly to prevent interruptions in their patient's drug therapy and counsel affected patients appropriately.

### Additional Information

#### For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641.

#### For all other Health Care Providers and Patients:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.